blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2688874

EP2688874 - 1,3,5-SUBSTITUTED 3-PIPERAZINE- OR 3-PIPERIDINE-1,2,4-TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE [Right-click to bookmark this link]
Former [2014/05]NOVEL SUBSTITUTED TRIAZOLYL PIPERAZINE AND TRIAZOLYL PIPERIDINE DERIVATIVES AS GAMMA SECRETASE MODULATORS
[2014/41]
StatusNo opposition filed within time limit
Status updated on  08.01.2016
Database last updated on 13.07.2024
Most recent event   Tooltip12.10.2018Lapse of the patent in a contracting state
New state(s): AL		published on 14.11.2018  [2018/46]
Applicant(s)For all designated states
Janssen Pharmaceuticals, Inc.
1125 Trenton-Harbourton Road
Titusville, NJ 08560 / US
For all designated states
Cellzome Limited
980 Great West Road
Brentford, Middlesex
TW8 9GS / GB
[N/P]
Former [2014/05]For all designated states
Janssen Pharmaceuticals, Inc.
1125 Trenton-Harbourton Road
Titusville, NJ 08560 / US
For all designated states
Cellzome Limited
980 Great West Road
Brentford, Middlesex
TW8 9GS / GB
Inventor(s)01 / BISCHOFF, François, Paul
c/o Janssen Pharmaceutica NV
Turnhoutseweg 30
B-2340 Beerse / BE
02 / VELTER, Adriana, Ingrid
c/o Janssen Pharmaceutica NV
Turnhoutseweg 30
B-2340 Beerse / BE
03 / VAN BRANDT, Sven, Franciscus, Anna
c/o Janssen Pharmaceutica NV
Turnhoutseweg 30
B-2340 Beerse / BE
04 / BERTHELOT, Didier, Jean-Claude
c/o Janssen Pharmaceutica NV
Turnhoutseweg 30
B-2340 Beerse / BE
 [2014/05]
Representative(s)Garcia Prieto, Maria
Johnson & Johnson
Patent Law Department
Turnhoutseweg 30
2340 Beerse / BE
[N/P]
Former [2014/05]Garcia Prieto, Maria
Janssen Pharmaceutica N.V.
Turnhoutseweg 30
2340 Beerse / BE
Application number, filing date12710928.822.03.2012
WO2012EP55079
Priority number, dateEP2011015963924.03.2011         Original published format: EP 11159639
[2014/05]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2012126984
Date:27.09.2012
Language:EN
[2012/39]
Type: A1 Application with search report 
No.:EP2688874
Date:29.01.2014
Language:EN
The application published by WIPO in one of the EPO official languages on 27.09.2012 takes the place of the publication of the European patent application.
[2014/05]
Type: B1 Patent specification 
No.:EP2688874
Date:04.03.2015
Language:EN
[2015/10]
Search report(s)International search report - published on:EP27.09.2012
ClassificationIPC:C07D249/10, A61K31/4196
[2014/05]
CPC:
C07D403/04 (EP,CN,KR,US); C07D401/04 (CN); A61K31/496 (KR);
A61P25/00 (EP); A61P25/16 (EP); A61P25/28 (EP);
A61P43/00 (EP); C07D249/10 (EP,US); C07D249/14 (CN);
C07D401/12 (CN); C07D401/14 (EP,CN,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/05]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:1,3,5-SUBSTITUIERTE 3-PIPERAZIN- ODER 3-PIPERIDIN-1,2,4-TRIAZOL DERIVATE ALS GAMMA-SECRETASE-MODULATOREN ZUR BEHANDLUNG VON ALZHEIMER'S ERKRANKUNG[2014/42]
English:1,3,5-SUBSTITUTED 3-PIPERAZINE- OR 3-PIPERIDINE-1,2,4-TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE[2014/42]
French:DÉRIVÉS DU 3-PIPERAZINE- OU 3-PIPERIDINE-1,2,4-TRIAZOLE SUBSTITUÉS 1,3,5 EN TANT QUE MODULATEURS DE LA SECRÉTASE GAMMA POUR LE TRAITEMENT DE LA MALADIE DE ALZHEIMER[2014/42]
Former [2014/05]NEUARTIGE SUBSTITUIERTE TRIAZOLYL-PIPERAZIN- UND TRIAZOLYL-PIPERIDIN-DERIVATE ALS GAMMA-SEKRETASE-MODULATOREN
Former [2014/05]NOVEL SUBSTITUTED TRIAZOLYL PIPERAZINE AND TRIAZOLYL PIPERIDINE DERIVATIVES AS GAMMA SECRETASE MODULATORS
Former [2014/05]NOUVEAUX DÉRIVÉS DE TRIAZOLYLPIPÉRAZINE ET TRIAZOLYLPIPÉRIDINE SUBSTITUÉS À TITRE DE MODULATEURS DE GAMMA SÉCRÉTASES
Entry into regional phase24.10.2013National basic fee paid 
24.10.2013Designation fee(s) paid 
24.10.2013Examination fee paid 
Examination procedure24.10.2013Examination requested  [2014/05]
22.09.2014Communication of intention to grant the patent
12.01.2015Fee for grant paid
12.01.2015Fee for publishing/printing paid
12.01.2015Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  22.09.2014
Opposition(s)07.12.2015No opposition filed within time limit [2016/06]
Fees paidRenewal fee
31.03.2014Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU22.03.2012
AL04.03.2015
AT04.03.2015
BG04.03.2015
CY04.03.2015
CZ04.03.2015
DK04.03.2015
EE04.03.2015
FI04.03.2015
HR04.03.2015
LT04.03.2015
LV04.03.2015
MC04.03.2015
MK04.03.2015
MT04.03.2015
NL04.03.2015
PL04.03.2015
RO04.03.2015
RS04.03.2015
SI04.03.2015
SK04.03.2015
SM04.03.2015
TR04.03.2015
LU22.03.2015
NO04.06.2015
GR05.06.2015
IS04.07.2015
PT06.07.2015
[2018/46]
Former [2018/31]HU22.03.2012
AT04.03.2015
BG04.03.2015
CY04.03.2015
CZ04.03.2015
DK04.03.2015
EE04.03.2015
FI04.03.2015
HR04.03.2015
LT04.03.2015
LV04.03.2015
MC04.03.2015
MK04.03.2015
MT04.03.2015
NL04.03.2015
PL04.03.2015
RO04.03.2015
RS04.03.2015
SI04.03.2015
SK04.03.2015
SM04.03.2015
TR04.03.2015
LU22.03.2015
NO04.06.2015
GR05.06.2015
IS04.07.2015
PT06.07.2015
Former [2018/02]HU22.03.2012
AT04.03.2015
BG04.03.2015
CY04.03.2015
CZ04.03.2015
DK04.03.2015
EE04.03.2015
FI04.03.2015
HR04.03.2015
LT04.03.2015
LV04.03.2015
MC04.03.2015
MT04.03.2015
NL04.03.2015
PL04.03.2015
RO04.03.2015
RS04.03.2015
SI04.03.2015
SK04.03.2015
SM04.03.2015
TR04.03.2015
LU22.03.2015
NO04.06.2015
GR05.06.2015
IS04.07.2015
PT06.07.2015
Former [2017/39]HU22.03.2012
AT04.03.2015
BG04.03.2015
CY04.03.2015
CZ04.03.2015
DK04.03.2015
EE04.03.2015
FI04.03.2015
HR04.03.2015
LT04.03.2015
LV04.03.2015
MC04.03.2015
MT04.03.2015
NL04.03.2015
PL04.03.2015
RO04.03.2015
RS04.03.2015
SI04.03.2015
SK04.03.2015
SM04.03.2015
TR04.03.2015
NO04.06.2015
GR05.06.2015
IS04.07.2015
PT06.07.2015
Former [2017/03]AT04.03.2015
CZ04.03.2015
DK04.03.2015
EE04.03.2015
FI04.03.2015
HR04.03.2015
LT04.03.2015
LV04.03.2015
MC04.03.2015
MT04.03.2015
NL04.03.2015
PL04.03.2015
RO04.03.2015
RS04.03.2015
SI04.03.2015
SK04.03.2015
NO04.06.2015
GR05.06.2015
IS04.07.2015
PT06.07.2015
Former [2016/12]AT04.03.2015
CZ04.03.2015
DK04.03.2015
EE04.03.2015
FI04.03.2015
HR04.03.2015
LT04.03.2015
LV04.03.2015
MC04.03.2015
NL04.03.2015
PL04.03.2015
RO04.03.2015
RS04.03.2015
SI04.03.2015
SK04.03.2015
NO04.06.2015
GR05.06.2015
IS04.07.2015
PT06.07.2015
Former [2016/07]AT04.03.2015
CZ04.03.2015
DK04.03.2015
EE04.03.2015
FI04.03.2015
HR04.03.2015
LT04.03.2015
LV04.03.2015
MC04.03.2015
NL04.03.2015
PL04.03.2015
RO04.03.2015
RS04.03.2015
SK04.03.2015
NO04.06.2015
GR05.06.2015
IS04.07.2015
PT06.07.2015
Former [2016/06]AT04.03.2015
CZ04.03.2015
EE04.03.2015
FI04.03.2015
HR04.03.2015
LT04.03.2015
LV04.03.2015
MC04.03.2015
NL04.03.2015
PL04.03.2015
RO04.03.2015
RS04.03.2015
SK04.03.2015
NO04.06.2015
GR05.06.2015
IS04.07.2015
PT06.07.2015
Former [2015/50]AT04.03.2015
CZ04.03.2015
EE04.03.2015
FI04.03.2015
HR04.03.2015
LT04.03.2015
LV04.03.2015
NL04.03.2015
PL04.03.2015
RO04.03.2015
RS04.03.2015
SK04.03.2015
NO04.06.2015
GR05.06.2015
IS04.07.2015
PT06.07.2015
Former [2015/49]AT04.03.2015
CZ04.03.2015
EE04.03.2015
FI04.03.2015
HR04.03.2015
LT04.03.2015
LV04.03.2015
NL04.03.2015
RO04.03.2015
RS04.03.2015
SK04.03.2015
NO04.06.2015
GR05.06.2015
PT06.07.2015
Former [2015/41]AT04.03.2015
FI04.03.2015
HR04.03.2015
LT04.03.2015
LV04.03.2015
NL04.03.2015
RS04.03.2015
NO04.06.2015
GR05.06.2015
Former [2015/39]AT04.03.2015
FI04.03.2015
HR04.03.2015
LT04.03.2015
LV04.03.2015
RS04.03.2015
NO04.06.2015
GR05.06.2015
Former [2015/38]AT04.03.2015
FI04.03.2015
HR04.03.2015
LT04.03.2015
NO04.06.2015
GR05.06.2015
Former [2015/37]FI04.03.2015
HR04.03.2015
LT04.03.2015
NO04.06.2015
GR05.06.2015
Former [2015/36]FI04.03.2015
HR04.03.2015
LT04.03.2015
NO04.06.2015
Former [2015/35]LT04.03.2015
NO04.06.2015
Cited inInternational search[AD]WO2011006903  (ORTHO MCNEIL JANSSEN PHARM [US], et al) [AD] 1-14 * page 19 - page 20 * * examples B1,B2 * * claims 1,9-11 *
by applicantUS2002128319
 WO2009103652
 WO2009032277
 WO2010010188
 WO2010098495
 WO2008099210
 WO2008100412
    - TANZI; BERTRAM, CELL, (2005), vol. 120, page 545
    - STEINER, CURR. ALZHEIMER RESEARCH, (2004), vol. 1, no. 3, pages 175 - 181
    - MAJAUX ET AL., DRUG DISCOVERY TODAY: THERAPEUTIC STRATEGIES, (2004), vol. 1, pages 1 - 6
    - LARNER, "Secretases as therapeutics targets in AD: patents 2000 - 2004", EXPERT OPIN. THER. PATENTS, (2004), vol. 14, doi:doi:10.1517/13543776.14.10.1403, pages 1403 - 1420, XP002404250

DOI:   http://dx.doi.org/10.1517/13543776.14.10.1403
    - ERIKSEN, J. CLIN. INVEST., (2003), vol. 112, page 440
    - PERETTO ET AL., J. MED. CHEM., (2005), vol. 48, pages 5705 - 5720
    - SCHWEISGUTH F, CURR. BIOL., (2004), vol. 14, page R129
    - CITRON ET AL., NATURE MEDICINE, (1997), vol. 3, page 67
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.